Showcases Stock ranks Forex

Bristol-Myers Squibb Company (BMY)
67.68  0.7 (1.05%) 03-24 16:00
Open: 67.2 Pre. Close: 66.98
High: 67.775 Low: 66.69
Volume: 6,058,833 Market Cap: 142,045(M)
Stock Technical Analysis
Target: Six months: 81.08
One year: 84.07
Support: Support1: 65.28
Support2: 54.31
Resistance: Resistance1: 69.42
Resistance2: 71.98
Pivot: 67.11
Moving Averages: MA(5): 67.33
MA(20): 67.67
MA(100): 73.51
MA(250): 73.78
MACD: MACD(12,26): -1.02
Signal(12,26,9): -1.23
%K %D: %K(14,3): 45.92
%D(3): 45.09
RSI: RSI(14): 44.27
52-Week: High: 81.44
Low: 65.28
Change(%): -8.2
Average Vol(K): 3-Month: 8118
10-Days: 9262
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 67.814 - 68.148 68.148 - 68.487
Low: 65.898 - 66.247 66.247 - 66.601
Close: 67.118 - 67.672 67.672 - 68.233
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

[ BMY ] has closed below upper band by 31.6%. Bollinger Bands are 47.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Stock chart
Stock News
Sat, 25 Mar 2023
Guru Fundamental Report for BMY - Nasdaq

Fri, 24 Mar 2023
Wesbanco Bank Inc. Boosts Stock Holdings in Bristol-Myers Squibb ... - MarketBeat

Thu, 23 Mar 2023
Hunter Perkins Capital Management LLC sells 31,100 Bristol-Myers ... - Best Stocks

Thu, 23 Mar 2023
Investment Partners LTD. Has $1.06 Million Stock Position in Bristol ... - MarketBeat

Wed, 22 Mar 2023
Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer? - Forbes

Wed, 15 Mar 2023
Bristol Myers Squibb Announces Progress Toward Long-Term ... - Bristol-Myers Squibb

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. (M) 2100.00
Shares Float (M) 2100.00
% Held by Insiders 0.07
% Held by Institutions 78.84
Shares Short (K) 17020
Shares Short Prior Month (K) 20720
Stock Financials
EPS 2.910
Book Value (p.s.) 14.810
Profit Margin 13.71
Operating Margin 21.40
Return on Assets (ttm) 6.0
Return on Equity (ttm) 18.9
Qtrly Rev. Growth -4.8
Gross Profit (p.s.) 17.324
Sales Per Share 21.981
EBITDA (p.s.) 9.600
Qtrly Earnings Growth -11.40
Operating Cash Flow (M) 13070.00
Levered Free Cash Flow (M) 13830.00
Stock Valuation
PE Ratio 23.26
PEG Ratio 2.05
Price to Book value 4.57
Price to Sales 3.08
Price to Cash Flow 10.87
Stock Dividends
Dividend 0.570
Dividend Yield 0.01
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android